C4 Therapeutics (Nasdaq: CCCC) reported that the independent directors on its Organization, Leadership and Compensation Committee approved an inducement grant of non-qualified stock options to purchase 162,880 shares of common stock for one new employee, effective August 10, 2026.
According to C4 Therapeutics, the grant was made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing price of C4T’s common stock on the grant date. The options vest over four years: 25% after one year, then the remainder in 36 equal monthly installments, contingent on continued employment.
Loading...
Loading translation...
Positive
Inducement option grant of 162,880 shares to attract key hire
Exercise price set at fair market value on August 10, 2026
The prior comparable grant carried a -3.42% 24-hour reaction, providing a direct historical comparat...
Analysis
The prior comparable grant carried a -3.42% 24-hour reaction, providing a direct historical comparator. The current award has four-year vesting; CCCC also has a confirmed but not effective S-3 shelf.
Key Figures
Shares under option:162,880 sharesGrant date:August 10, 2026Vesting period:four years+2 more
5 metrics
Shares under option162,880 sharesInducement Grant to one new employee
Grant dateAugust 10, 2026Inducement Grant
Vesting periodfour yearsOption vesting schedule
Initial vesting25% of sharesFirst-year anniversary of employee start date
Subsequent vestingthirty-six equal monthly installmentsRemainder of the option shares
"approved the grant of non-qualified stock options to purchase 162,880 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
inducement grantfinancial
"the “Inducement Grant”"
An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.
Nasdaq Listing Rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"has an exercise price per share that is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestfinancial
"The Inducement Grant will vest over a four-year period"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on August 10, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date.The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.
About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
What did C4 Therapeutics (CCCC) announce on August 10, 2026 regarding stock options?
C4 Therapeutics announced an inducement grant of non-qualified stock options for 162,880 shares to a new employee. According to C4 Therapeutics, the grant was approved by independent directors and made effective on August 10, 2026 as a material inducement to employment.
How many shares are included in the C4 Therapeutics (CCCC) inducement grant and who receives them?
The inducement grant covers options to purchase 162,880 shares of C4 Therapeutics common stock, awarded to a single new employee. According to C4 Therapeutics, the grant is intended as a material inducement for this individual to join and remain with the company.
What is the exercise price of the C4 Therapeutics (CCCC) inducement stock options granted on August 10, 2026?
The exercise price equals the closing price of C4 Therapeutics common stock on the August 10, 2026 grant date. According to C4 Therapeutics, this pricing aligns the option’s strike price with fair market value at the time of grant under typical equity compensation practice.
How do the C4 Therapeutics (CCCC) inducement stock options vest over time?
The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s start date. According to C4 Therapeutics, the remaining shares vest in 36 equal monthly installments, subject to the employee’s continued employment through each vesting date.
Why did C4 Therapeutics (CCCC) use Nasdaq Listing Rule 5635(c)(4) for this inducement grant?
C4 Therapeutics granted the options as a material inducement to the new employee’s hiring under Nasdaq Listing Rule 5635(c)(4). According to C4 Therapeutics, this rule allows equity awards outside shareholder-approved plans when used specifically to attract new employees.
What potential impact could the C4 Therapeutics (CCCC) inducement grant have on existing shareholders?
If fully exercised, the options could increase the number of C4 Therapeutics shares outstanding by 162,880, creating potential dilution. According to C4 Therapeutics, the grant is designed to attract and retain talent, seeking to align the employee’s interests with shareholders over time.
